Targeting B cells in treatment of autoimmunity

S. Elizabeth Franks, Andrew Getahun, P. Mark Hogarth, John C Cambier

Research output: Contribution to journalReview ArticleOtherpeer-review

34 Citations (Scopus)

Abstract

B cells have emerged as effective targets for therapeutic intervention in autoimmunities in which the ultimate effectors are antibodies, as well as those in which T cells are primary drivers of inflammation. Proof of this principle has come primarily from studies of the efficacy of Rituximab, an anti-CD20 mAb that depletes B cells, in various autoimmune settings. These successes have inspired efforts to develop more effective anti-CD20s tailored for specific needs, as well as biologicals and small molecules that suppress B cell function without the risks inherent in B cell depletion. Here we review the current status of B cell-targeted therapies for autoimmunity.

Original languageEnglish
Pages (from-to)39-45
Number of pages7
JournalCurrent Opinion in Immunology
Volume43
DOIs
Publication statusPublished - 1 Dec 2016

Cite this